You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020304035
Dec 202012507
Jan 20217406
Feb 20216706
Mar 2021148051
Apr 2021136029
May 202151018
Jun 20210025
Jul 20210024
Aug 20210030
Sep 20210036
Oct 2021124040
Nov 2021194041
Dec 2021136024
Jan 2022166021
Feb 2022174039
Mar 2022316018
Apr 2022240026
May 202215008
Jun 2022148014
Jul 2022170015
Aug 202213008
Sep 202211208
Oct 202270014
Nov 202262010
Dec 20224803
Jan 202360018
Feb 202376012
Mar 20235008
Apr 202342011
May 20233403
Jun 20234408
Jul 202354014
Aug 20233807
Sep 202350012
Oct 20234404
Nov 20234207
Dec 20237001
Jan 20245807
Feb 20243604
Mar 20246005
Apr 20243404
May 20245204
Jun 20246401
Jul 20245804
Aug 20246208
Sep 20245808
Oct 20243804
Nov 20242603
Dec 20242804
Jan 20256804
Feb 20251004
Mar 2025007
Apr 20250011
May 2025004
Jun 2025007
Total44010754